Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
Summary
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
Description
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source